Jacqueline H. Starrett

Also affiliated with Nanospectra Biosciences (United States)

MedicineBiochemistry, Genetics and Molecular Biology

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations”.

Efficacy of Osimertinib in Patients with Lung Cancer Positive for Uncommon EGFR Exon 19 Deletion Mutations

Clinical Cancer Research(2023)10.1158/1078-0432.ccr-22-3497

N/A

0.564DataRank · unranked

42 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Paul Stockhammer, Iris K. van Alderwerelt van Rosenburgh, Anna Wurtz +16 more

Drug Sensitivity and Allele Specificity of First-Line Osimertinib Resistance EGFR Mutations

Cancer Research(2020)10.1158/0008-5472.can-19-3819

N/A

0DataRank · unranked

60 citations

Alexis Guernet, Maria Emanuela Cuomo, Kamrine E. Poels, Iris K. van Alderwerelt van Rosenburgh, Amy Nagelberg +19 more

Targeting de novo lipogenesis and the Lands cycle induces ferroptosis in KRAS-mutant lung cancer

Nature Communications(2022)10.1038/s41467-022-31963-4

N/A

0DataRank · unranked

172 citations

Cristina Andreani, Gonçalo Vale, Stefano Berto, Margherita Melegari, A. Colleen Crouch +17 more

Efficacy of osimertinib in patients with EGFR mutant lung cancer harboring the uncommon exon 19 deletion, L747_A750>P.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e21112

N/A

0DataRank · unranked

0 citations

Jacqueline V. Aredo, Jacqueline H. Starrett, Anna Wurtz, Zofia Piotrowska, Andrew J. Piper‐Vallillo +13 more